Considerable commercial interest in Alzheimer's pipeline despite high rate of attrition, report says

24 February 2015

Despite a high rate of attrition, there is a considerable level of commercial interest in the Alzheimer’s disease treatment pipeline, according to research from business intelligence provider GBI Research.

The total number of active drugs in the Alzheimer’s treatment pipeline currently stands at 583, implying a high level of commercial interest. The latest GBI report states that 77% of pipeline drugs are in early stages of development, such as discovery and preclinical phases, whereas therapeutics in Phase III development make up just 3% of the overall pipeline, reflecting a high rate of attrition by late stages.

Alzheimer's failure rate three times higher than all of pharma

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK